HeartWare upgraded to Outperform from Perform at Oppenheimer Oppenheimer upgraded HeartWare to Outperform with a $103 price target. Note shares were also upgraded this morning at BTIG and downgraded to Sell at Goldman Sachs.
Update suggests HeartWare CE mark trial on track, says Wells Fargo Wells Fargo said the clinicaltrials.gov posting for HeartWare's MVAD CE Mark trial, which had not been changed since April 2013, was updated on October 16 and now indicates the trial is scheduled to start in April 2015. Wells expects HeartWare to update on MVAD on its Q3 call next week, but the firm said that it does not expect any major surprises based on the updated posting. Wells Fargo maintains its Market Perform rating on HeartWare.